Form 4: Jupiter Neurosciences Director Receives Stock Options
Director Equity Grant
Director Nicholas H. Hemmerly was granted 100,000 stock options in Jupiter Neurosciences, Inc. under the 2025 Equity Incentive Plan.
Summary
- Director Nicholas H. Hemmerly received a grant of 100,000 stock options.
- The options have an exercise price of $0.2783 per share.
- The grant was issued under the company's 2025 Equity Incentive Plan.
- The options vest over a three-year period starting September 2, 2026, in equal quarterly installments.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential future dilution of existing shareholders upon the exercise of these options.
Risks
- The value of the options is dependent on the future market performance of the company's common stock.
- Vesting is subject to the director's continued service to the company.
Future Outlook
The options vest over three years, indicating a long-term retention strategy for the director.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized to achieve long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of a three-year vesting schedule is consistent with standard equity incentive practices for small-cap biotech firms.
- Granting options at the current market price is a standard mechanism to align director compensation with shareholder interests.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 100,000 options under the 2025 Equity Incentive Plan. | 06/02/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution if options are exercised in the future.
Next Steps
- Vesting of options to commence on September 2, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/02/2026 | Date of the option grant transaction. |
| 09/02/2026 | Commencement date for the vesting of the options. |
| 06/02/2036 | Expiration date of the granted stock options. |
Keywords
Jupiter Neurosciences, JUNS, Form 4, Stock Options, Insider Trading, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.